Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 6, 2012 - Issue 5
Submit an article Journal homepage
198
Views
26
CrossRef citations to date
0
Altmetric
Review

Drug choices in autoimmune hepatitis: Part A – steroids

Albert J Czaja Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. [email protected]
Pages 603-615 | Published online: 10 Jan 2014

References

  • Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q. J. Med. 40(158), 159–185 (1971).
  • Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63(5), 820–833 (1972).
  • Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1(7806), 735–737 (1973).
  • Manns MP, Czaja AJ, Gorham JD et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 51(6), 2193–2213 (2010).
  • Strassburg CP, Manns MP. Therapy of autoimmune hepatitis. Best Pract. Res. Clin. Gastroenterol. 25(6), 673–687 (2011).
  • Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin. Drug Saf. 7(3), 319–333 (2008).
  • Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am. J. Gastroenterol. 99(8), 1510–1516 (2004).
  • Miyake Y, Iwasaki Y, Terada R et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J. Hepatol. 43(6), 951–957 (2005).
  • Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am. J. Gastroenterol. 102(5), 1005–1012 (2007).
  • Wörns MA, Teufel A, Kanzler S et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am. J. Gastroenterol. 103(1), 138–146 (2008).
  • Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 139(1), 58–72.e4 (2010).
  • Czaja AJ. Advances in the Current Treatment of Autoimmune Hepatitis. Dig. Dis. Sci. 57(8), 1996–2010 (2012).
  • Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35(4), 890–897 (2002).
  • Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation. Ann. Gastroenterol. Hepatol. 1, 79–89 (2010).
  • Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95(2), 448–453 (1988).
  • Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z. Gastroenterol. 39(5), 339–41, 344 (2001).
  • Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J. Hepatol. 51(1), 161–167 (2009).
  • Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 8(6), 505–513 (2002).
  • Czaja AJ. Diagnosis, Pathogenesis, and Treatment of Autoimmune Hepatitis After Liver Transplantation. Dig. Dis. Sci. 57(9), 2248–2266 (2012).
  • Neuberger J. Transplantation for autoimmune hepatitis. Semin. Liver Dis. 22(4), 379–386 (2002).
  • Khalaf H, Mourad W, El-Sheikh Y et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant. Proc. 39(4), 1166–1170 (2007).
  • Hayashi M, Keeffe EB, Krams SM et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl. Surg. 4(3), 208–214 (1998).
  • Vogel A, Heinrich E, Bahr MJ et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin. Transplant. 18(1), 62–69 (2004).
  • Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl. Surg. 5(5), 375–380 (1999).
  • Campsen J, Zimmerman MA, Trotter JF et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 14(9), 1281–1286 (2008).
  • Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol. Res. 37(Suppl. 3), S462 (2007).
  • Liberal R, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. Clin. Gastroenterol. Hepatol. 10(4), 346–353 (2012).
  • Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16(11), 876–883 (1975).
  • Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr. Pharm. Des. 17(29), 3120–3140 (2011).
  • Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol. 3(3), 269–291 (2009).
  • Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig. Dis. Sci. 55(10), 2712–2726 (2010).
  • Czaja AJ. Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis. Part-I. Inflamm. Allergy Drug Targets PMID: 22563779 (2012) (Epub ahead of print).
  • Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm. Allergy Drug Targets PMID: 22563780 (2012) (Epub ahead of print).
  • Czaja AJ. Autoimmune hepatitis: focusing on treatments other than steroids. Can. J. Gastroenterol. (2012) (In Press).
  • Czaja AJ, Bianchi FB, Carpenter HA et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 41(1), 207–215 (2005).
  • Manns MP. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology 140(7), 1874–1876 (2011).
  • Schalm SW, Summerskill WH, Go VL. Development of radioimmunoassays for prednisone and prednisolone. Application to studies of hepatic metabolism of prednisone. Mayo Clin. Proc. 51(12), 761–766 (1976).
  • Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44(1), 61–98 (2005).
  • Schalm SW, Summerskill WH, Go VL. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology 72(5 Pt 1), 910–913 (1977).
  • Uribe M, Schalm SW, Summerskill WH, Go VL. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut 19(12), 1131–1135 (1978).
  • Uribe M, Go VL. Corticosteroid pharmacokinetics in liver disease. Clin. Pharmacokinet. 4(3), 233–240 (1979).
  • Uribe M, Summerskill WH, Go VL. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin. Pharmacokinet. 7(5), 452–459 (1982).
  • Uribe M, Go VL, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J. Clin. Gastroenterol. 6(4), 331–335 (1984).
  • Diederich S, Hanke B, Burkhardt P et al. Metabolism of synthetic corticosteroids by 11 β-hydroxysteroid-dehydrogenases in man. Steroids 63(5–6), 271–277 (1998).
  • Diederich S, Eigendorff E, Burkhardt P et al. 11-β-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J. Clin. Endocrinol. Metab. 87(12), 5695–5701 (2002).
  • Maser E, Völker B, Friebertshäuser J. 11 β-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41(7), 2459–2465 (2002).
  • Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment. Pharmacol. Ther. 10(Suppl. 2), 81–90; discussion 91 (1996).
  • De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109(1), 16–22 (2000).
  • Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod. Asp. Immunobiol., 2, 78–82 (2001).
  • Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev. Gastroenterol. Hepatol. 1(1), 113–128 (2007).
  • Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am. J. Gastroenterol. 96(4), 1224–1231 (2001).
  • Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J. Hepatol. 40(4), 646–652 (2004).
  • Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. 60(5), 563–572 (1996).
  • Migita K, Eguchi K, Kawabe Y et al. Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 63(4), 583–587 (1997).
  • Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58(1), 91–97 (2001).
  • Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275(4), 2247–2250 (2000).
  • Murphy FR, Issa R, Zhou X et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 277(13), 11069–11076 (2002).
  • Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39(6), 1631–1638 (2004).
  • Lewis GP, Jusko WJ, Graves L, Burke CW. Prednisone side-effects and serum-protein levels. A collaborative study. Lancet 2(7728), 778–780 (1971).
  • Centeno F, Robles G, Uribe M, Lozada SG, Suárez GI. Nomogram for prednisone-prednisolone adjustment dose in patients with hypoalbuminemia. Rev. Invest. Clin. 30(1), 35–39 (1978).
  • Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm. Drug Dispos. 15(2), 163–172 (1994).
  • Yates CR, Chang C, Kearbey JD et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm. Res. 20(11), 1794–1803 (2003).
  • Ost L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation 44(4), 533–535 (1987).
  • Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 28(6), 485–518 (1984).
  • Mittmann N, Hernandez P, Mellström C, Brannman L, Welte T. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 29(5), 403–414 (2011).
  • Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev. Clin. Immunol. 7(4), 419–428 (2011).
  • Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 9(10), 881–890 (2011).
  • Straumann A, Conus S, Degen L et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 9(5), 400–409.e1 (2011).
  • Wiegand J, Schüler A, Kanzler S et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 25(5), 927–934 (2005).
  • Csepregi A, Röcken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J. Gastroenterol. 12(9), 1362–1366 (2006).
  • Manns MP, Bahr MJ, Woynarowski M et al. Budesonide 3 mg TID is superior to prednisolone in combination with azathioprine in the treatment of autoimmune hepatitis. J. Hepatol. 48 (Suppl. 2), Abstract S369 (2008).
  • Zandieh I, Krygier D, Wong V et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can. J. Gastroenterol. 22(4), 388–392 (2008).
  • Manns MP, Woynarowski M, Kreisel W et al.; European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139(4), 1198–1206 (2010).
  • Snider KR, Potter TG. Budesonide for the treatment of autoimmune hepatitis. Ann. Pharmacother. 45(9), 1144–1150 (2011).
  • Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther. 8(6), 585–590 (1994).
  • Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J. Gastroenterol. 9(12), 2681–2685 (2003).
  • Efe C, Ozaslan E, Kav T et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun. Rev. 11(5), 330–334 (2012).
  • McKay DM, Brattsand R, Wieslander E, Fung M, Croitoru K, Perdue MH. Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation. J. Pharmacol. Exp. Ther. 277(1), 403–410 (1996).
  • Strandberg K, Blidberg K, Sahlander K, Palmberg L, Larsson K. Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Pulm. Pharmacol. Ther. 23(4), 316–323 (2010).
  • Longui CA, Santos MC, Formiga CB et al. Antiproliferative and apoptotic potencies of glucocorticoids: nonconcordance with their antiinflammatory and immunosuppressive properties. Arq. Bras. Endocrinol. Metabol. 49(3), 378–383 (2005).
  • von Scheele I, Larsson K, Palmberg L. Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cells. Inhal. Toxicol. 22(6), 493–499 (2010).
  • Hofkens W, van den Hoven JM, Pesman GJ et al. Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: comparison of prednisolone with budesonide. Int. J. Pharm. 416(2), 493–498 (2011).
  • Ryrfeldt A, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Respir. Dis. Suppl. 122, 86–95 (1982).
  • Dilger K, Alberer M, Busch A et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn’s disease. Aliment. Pharmacol. Ther. 23(3), 387–396 (2006).
  • Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin. Pharmacokinet. 40(10), 723–751 (2001).
  • Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin. Pharmacokinet. 43(12), 803–821 (2004).
  • Jönsson G, Aström A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos. 23(1), 137–142 (1995).
  • Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm. Bowel Dis. 10(5), 578–583 (2004).
  • Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38(1), 196–202 (2003).
  • Mederacke I, Helfritz F, Puls F et al. Budd–Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann. Hepatol. 11(1), 143–144 (2012).
  • Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 119(5), 1312–1316 (2000).
  • Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J. Hepatol. 54(4), 837–839 (2011).
  • Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 29(6), 816–823 (2009).
  • Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract. Res. Clin. Gastroenterol. 25(6), 689–700 (2011).
  • Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis J. Hepatol. 31(5), 929–938 (1999).
  • Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 46(4), 1138–1145 (2007).
  • Yeoman AD, Westbrook RH, Zen Y et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 53(3), 926–934 (2011).
  • Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin. Liver Dis. 6(3), 799–824 (2002).
  • Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol. 4(4), 429–443 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.